Published in Gene Therapy Weekly, January 19th, 2006
Under the terms of the agreement, Genzyme will acquire all of Avigen's non-pain related AAV assets. The assets include all rights to an extensive patent estate and Avigen's Parkinson's disease clinical trial program, which is in a phase I /II study currently underway at University of California, San Francisco (UCSF).
Genzyme will make an upfront cash payment of $12 million to Avigen, with additional milestone payments and royalty payments on all products developed under Avigen's comprehensive AAV intellectual property (IP) portfolio, including the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.